|
Cocaine Dependence
|
0.520 |
Therapeutic
|
disease |
CTD_human |
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.
|
20494958 |
2010 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
CTD_human |
Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: studies with preferential antagonists in squirrel monkeys.
|
20494958 |
2010 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
CTD_human |
The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
|
18566292 |
2008 |
|
Cocaine Dependence
|
0.520 |
Therapeutic
|
disease |
CTD_human |
The dopamine D3/D2 agonist (+)-PD-128,907 [(R-(+)-trans-3,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano[4,3-b]-1,4-oxazin-9-ol)] protects against acute and cocaine-kindled seizures in mice: further evidence for the involvement of D3 receptors.
|
18566292 |
2008 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
CTD_human |
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement.
|
17332411 |
2007 |
|
Cocaine Dependence
|
0.520 |
Therapeutic
|
disease |
CTD_human |
Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement.
|
17332411 |
2007 |
|
Cocaine Dependence
|
0.520 |
GeneticVariation
|
disease |
BEFREE |
Our data do not support a role for the dopamine D2 receptor gene TaqI A and dopamine D3 receptor gene BalI gene polymorphisms in the susceptibility to cocaine dependence in a Brazilian sample.
|
16094250 |
2005 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
PSYGENET |
Our data do not support a role for the dopamine D2 receptor gene TaqI A and dopamine D3 receptor gene BalI gene polymorphisms in the susceptibility to cocaine dependence in a Brazilian sample.
|
16094250 |
2005 |
|
Cocaine Dependence
|
0.520 |
Therapeutic
|
disease |
CTD_human |
Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior.
|
15100700 |
2004 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
CTD_human |
Increases in dopamine D3 receptor binding in rats receiving a cocaine challenge at various time points after cocaine self-administration: implications for cocaine-seeking behavior.
|
15100700 |
2004 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
PSYGENET |
BP 897, a selective dopamine D3 receptor ligand with therapeutic potential for the treatment of cocaine-addiction.
|
12847556 |
2003 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
PSYGENET |
These findings support a modest role of the DRD3 gene in susceptibility to cocaine dependence.
|
10523822 |
1999 |
|
Cocaine Dependence
|
0.520 |
Therapeutic
|
disease |
CTD_human |
These findings support a modest role of the DRD3 gene in susceptibility to cocaine dependence.
|
10523822 |
1999 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
BEFREE |
These findings support a modest role of the DRD3 gene in susceptibility to cocaine dependence.
|
10523822 |
1999 |
|
Cocaine Dependence
|
0.520 |
Biomarker
|
disease |
CTD_human |
These findings support a modest role of the DRD3 gene in susceptibility to cocaine dependence.
|
10523822 |
1999 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated in a randomized placebo-controlled clinical trial in patients with schizophrenia (Bitter et al.
|
31773210 |
2020 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our findings may help to improve the understanding of the relationship between 5-HT2A and DRD3 genotypes and schizophrenia pathogenesis.
|
31813806 |
2019 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated 15 single-nucleotide polymorphisms (SNPs) in DRD3 and four SNPs in BDNF for possible association with alcohol abuse or dependence in schizophrenia patients of European ancestry (N = 195).
|
29357295 |
2018 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
In combination with previous studies, these results suggest that cariprazine has a unique pharmacological profile and distinct dopamine D3 receptor-dependent mechanism of action that may be beneficial in the treatment of schizophrenia, bipolar disorder, and major depressive disorder.
|
28531264 |
2017 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
No association between dopamine D3 receptor gene rs6280" genes_norm="1814">Ser9Gly polymorphism (rs6280) and risk of schizophrenia: an updated meta-analysis.
|
29200860 |
2017 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
We previously reported that YQA31 is a dopamine D3 receptor antagonist with modest 5-HT1A receptor affinity and that it exhibits antipsychotic properties in animal models of schizophrenia.
|
29128790 |
2017 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Expression of the dopamine D3 (DRD3) receptor was significantly increased in clozapine-treated schizophrenia and covaried significantly with differentiated T cell classes in the CD4+ lineage.
|
27244229 |
2016 |
|
Schizophrenia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To assess the relationship between cognitive function, a proposed schizophrenia endophenotype, and two genetic polymorphisms related to dopamine function, catechol-O-methyl transferase (COMT) Val158Met and dopamine receptor 3 (DRD3) Ser9Gly.
|
26376054 |
2016 |
|
Schizophrenia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicated that DRD1, DRD2 and DRD3 may not be the susceptibility genes for schizophrenia in the Chinese Han population.
|
27591410 |
2016 |
|
Schizophrenia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The present study demonstrated that the mRNA expression levels of DRD3 in T lymphocytes were significantly different among controls, and in patients with psychotic disorder not otherwise specified (NOS) and schizophrenia/schizophreniform disorder.
|
26561806 |
2015 |